Changes in serum total and pancreatic amylase after administration of secretin and cholecystokinin-pancreozymin in patients with early and advanced chronic pancreatitis, and in normal subjects

Serum pancreatic isoamylase estimation by the inhibitor method as a diagnostic test for chronic pancreatitis

The diagnosis of chronic pancreatitis is often difficult to establish and may involve invasive diagnostic procedures. Serum pancreatic isoamylase has been estimated by the inhibitor method in controls and in 38 patients with known chronic pancreatitis in order to evaluate its use as a diagnostic test. The mean pancreatic isoamylase in those with chronic pancreatitis (68 +/- 77 IU/l) was significantly lower (p less than 0.005) than in controls (113 +/- 60 IU/l). The diagnostic sensitivity of pancreatic isoamylase was 50% (compared to total amylase 9%) and had a specificity of 95%. Stimulation tests with cholecystokinin and secretin failed to increase the sensitivity of the test. A low value of pancreatic isoamylase strongly supports a diagnosis of chronic pancreatitis and may obviate the need for further investigation.

Serum trypsin, alpha-amylase and lipase during bombesin stimulation in normal subjects and patients with pancreatic insufficiency

The effect of infusion of bombesin (60 pmol/kg 20 min) on pancreatic enzymes in serum was studied in 13 normal subjects and 12 patients with pancreatic insufficiency. In normal subjects administration of bombesin induced large increases in serum trypsin (p less than 0.01), while serum total alpha-amylase and pancreatic alpha-amylase did not change and serum lipase showed only a modest rise (0.01 less than p less than 0.05). Patients with pancreatic insufficiency had significantly lower serum concentrations of all enzymes studied (p less than 0.01) and in such patients bombesin did not change the concentrations of pancreatic enzymes in serum. It is concluded that determination of the serum trypsin response to bombesin may be of help in the diagnosis of pancreatic insufficiency.

Assessment of a rapid pancreatic isoamylase assay as a screening test for chronic pancreatic disease

A new, rapid assay for pancreatic isoamylase (PIA) has been evaluated in normal subjects and patients with either proven chronic pancreatic disease or diseases in which chronic pancreatitis commonly enters the differential diagnosis. A wide normal range limited the diagnostic usefulness of the test. In non-pancreatic disease the serum levels of PIA were normal in 107 of 109 patients with non-pancreatic disease, but only 3 of 16 patients with chronic pancreatitis and proven exocrine insufficiency had a low PIA level, and variable levels occurred in pancreatic carcinoma. These results suggest that measurement of serum PIA is of limited value as a screening test for chronic pancreatic disease.